Citius Pharmaceuticals Inc expected to post a loss of 4 cents a share - Earnings Preview

Published on December 09, 2022 03:19 AM PST

Citius Pharmaceuticals Inc expected to post a loss of 4 cents a share - Earnings Preview — Image source: ©2022 Kalkine Media®

* Citius Pharmaceuticals Inc is expected to show no change in quarterly revenue when it reports results on December 13 (estimated). * * Refinitiv's mean analyst estimate for Citius Pharmaceuticals Inc is for a loss of 4 cents per share. * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." * The mean earnings estimate of analysts was unchanged in the last three months. * Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $8, above its last closing price of $1.13. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI ENDING ARTESTIMAT IBES MET, SE % E® ESTIMATE MISSED Jun. 30 2022 -0.05 -0.05 -0.06 Missed -20 Mar. 31 2022 -0.07 -0.07 -0.05 Beat 28.6 Dec. 31 2021 -0.06 -0.06 -0.06 Met 0 Sep. 30 2021 -0.04 -0.04 -0.02 Beat 50 Jun. -0.06 -0.06 -0.06 Met 7.7 30 2021 Mar. 31 2021 -0.08 -0.07 -0.04 Beat 46.7 Dec. 31 2020 0.16 0.16 -0.15 Missed -193.7 Sep. 30 2020 -0.11 -0.10 -0.07 Beat 33.3 This summary was machine generated December 9 at 11:19 GMT. All figures in US dollars unless otherwise stated.

Reuters

Reuters -
94599 Posts
...

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.